Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months

BACKGROUND: In daily practice, anti-CGRP monoclonal antibodies (MAbs) may be useful in chronic migraine (CM) with medication overuse (MO), but data is limited. We evaluated their effectiveness in a real-life clinical cohort. METHODS: This is a prospective study conducted in CM patients with and with...

Descripción completa

Detalles Bibliográficos
Autores principales: Caronna, Edoardo, Gallardo, Victor José, Alpuente, Alicia, Torres-Ferrus, Marta, Pozo-Rosich, Patricia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2021
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8499507/
https://www.ncbi.nlm.nih.gov/pubmed/34620085
http://dx.doi.org/10.1186/s10194-021-01328-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8499507/
https://www.ncbi.nlm.nih.gov/pubmed/34620085
http://dx.doi.org/10.1186/s10194-021-01328-1

Ejemplares similares